Table 1: Randomized trials with neoadjuvant trastuzumab.

Study (ref.)No. of patientsClinical stageNeoadjuvant chemotherapypCR rate (%)cCR (%)Breast-conserving surgery rate (%)

Buzdar et al. [4, 5],
phase III
42II–IIIAP (4 c) → FEC (4 c) *Trastuzumab: 65% 
*No trastuzumab: 26%
Trastuzumab: 87%
No trastuzumab: 47%
Trastuzumab: 53%  
No trastuzumab: 56.5%
H2269s [6],
phase II
30II-IIIDoc + carboplatin
(4 c)
Trastuzumab: 40%  
No trastuzumab: 7.1%
NRNR
ABCSG-24
[7], phase III
90T1–4 (except T4d), any NED ± Cap (6 c) #Trastuzumab: 40%  
#No trastuzumab: 26.7%
NRTrastuzumab: 69%  
No trastuzumab: 79%
NOAH [8],
phase III
235T3N1, T4, or any T N2-3Doxo + P (3 c) → P (4c) → CMF (3 c) *Trastuzumab: 38%   
*No trastuzumab: 19%
Trastuzumab: 87%
No trastuzumab: 74%
Trastuzumab: 23%  
No trastuzumab: 13%
REMAGUS 2 [9], phase II 120II-IIIEC (4 c) → Doc (4 c) *Trastuzumab: 26%  
*No trastuzumab: 19%
Trastuzumab: 34%
No trastuzumab: 22%
Trastuzumab: 47%  
No trastuzumab: 47%

pCR: pathologic complete response; cCR: clinical complete response; NR: not reported; P: paclitaxel; FEC: 5-fluorouracil + epirubicin + cyclophosphamide; Doc: docetaxel; ED: epirubicin + docetaxel; Cap: capecitabine; Doxo: doxorubicine; CMF: cyclophosphamide + methotrexate + 5-fluoro-uracile; EC: epirubicin + cyclophosphamide.
pCR: *no invasive residual tumor in breast and axilla; no invasive residual tumor in breast only; #definition not reported.
[11].